糖尿病腎臟病市場規模、佔有率和成長分析（按藥物類別、類型、給藥途徑、最終用戶、分銷管道和地區）- 產業預測 2025-2032

2023 年全球糖尿病腎臟病市場規模價值 23 億美元，預計將從 2024 年的 24.4 億美元成長到 2032 年的 38.9 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

全球糖尿病腎臟病市場正在經歷顯著成長，這主要是由於糖尿病盛行率的上升和對有效治療方案的需求的增加。糖尿病已在世界範圍內達到流行病的程度，相當一部分受此影響的人群面臨糖尿病腎臟病的風險，這增加了對先進治療方案的需求。根據我們的分析，醫學研究的不斷進展導致了新的診斷工具的引入，例如生物標記和基因測試，從而增強了早期檢測和風險評估。此外，腎素-血管收縮素-醛固酮系統 (RAAS) 抑制劑和鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑等標靶治療藥物的出現，透過減緩疾病進展和減少併發症，顯著改善了疾病管理。這些突破正在推動市場創新、改善患者治療效果並促進市場大幅擴張。隨著醫療保健提供者注重早期療育和個人化治療，糖尿病腎臟病市場可望持續成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

糖尿病腎臟病市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概況
• 利尿劑
• 抗氧化發炎調節劑
• 血管收縮素受體阻斷劑
• 血管張力素轉化酵素抑制劑（ACE 抑制劑）
• 腎素抑制劑
• 鈣離子通道阻斷劑
• 其他

糖尿病腎臟病市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 1 型糖尿病
• 2 型糖尿病

糖尿病腎臟病市場規模依給藥途徑及複合年成長率（2025-2032）

• 市場概況
• 口服
• 腸外
• 其他

糖尿病腎臟病市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 居家護理
• 專業中心
• 其他

糖尿病腎臟病市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 網路藥局
• 零售藥局

糖尿病腎臟病市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Eli Lilly and Company（US）
• AstraZeneca（UK）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Sanofi（France）
• Merck & Co., Inc.（US）
• Daiichi Sankyo Company, Limited（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Boehringer Ingelheim（Germany）
• GlaxoSmithKline plc（UK）
• AbbVie Inc.（US）
• Vertex Pharmaceuticals（US）
• Amgen（US）
• Gilead Sciences, Inc.（US）
• Biogen（US）
• Regeneron Pharmaceuticals, Inc.（US）

結論和建議

Global Diabetic Nephropathy Market size was valued at USD 2.3 billion in 2023 and is poised to grow from USD 2.44 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global diabetic nephropathy market is witnessing substantial growth, primarily fueled by the rising prevalence of diabetes and the increasing need for effective treatment solutions. With diabetes reaching epidemic levels worldwide, a significant portion of the affected population is at risk of developing diabetic nephropathy, creating a growing demand for advanced therapeutic options. Our analysis reveals that continuous advancements in medical research have led to the introduction of novel diagnostic tools, such as biomarkers and genetic testing, enhancing early detection and risk assessment. Furthermore, the emergence of targeted therapies, including renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors, has significantly improved disease management by slowing disease progression and mitigating complications. These breakthroughs are driving innovation in the market, ensuring better patient outcomes and fostering substantial market expansion. As healthcare providers emphasize early intervention and personalized treatments, the diabetic nephropathy market is poised for continued growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Nephropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Nephropathy Market Segments Analysis

Global Diabetic Nephropathy Market is segmented by Drug Class, Type, Route of Administration, End-Users, Distribution Channel and Region. Based on Drug Class, the market is segmented into Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers and Others. Based on Type, the market is segmented into Type-1 Diabetes and Type-2 Diabetes. Based on Route of Administration, the market is segmented into Oral, Parental and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Nephropathy Market

Our analysis reveals that the rising healthcare expenditure, especially in emerging economies, is a key driver propelling the growth of the global diabetic nephropathy market. Increasing investments in healthcare infrastructure are improving access to advanced diagnostics, effective treatment modalities, and essential medications for diabetic nephropathy patients. Governments and private entities are allocating substantial resources to enhance disease management programs, early detection initiatives, and specialized care facilities. This growing financial commitment is fostering a more robust healthcare ecosystem, enabling patients to receive timely and comprehensive treatment. As healthcare budgets continue to expand, particularly in regions with a high diabetes burden, the diabetic nephropathy market is expected to witness sustained growth, driven by improved affordability and availability of critical medical interventions.

Restraints in the Global Diabetic Nephropathy Market

Our analysis reveals that the high cost of diabetic nephropathy treatment remains a significant restraint in the global market. Advanced therapeutic options, including SGLT2 inhibitors, RAAS inhibitors, and dialysis, impose a substantial financial burden on patients, particularly in low- and middle-income countries where healthcare reimbursement is limited. Additionally, kidney transplants, often the last resort for end-stage renal disease (ESRD) caused by diabetic nephropathy, involve extensive costs for surgery, post-operative care, and lifelong immunosuppressive therapy. This financial barrier leads to delayed treatment initiation, worsening disease progression, and higher mortality rates. Moreover, the lack of affordable generic alternatives further exacerbates accessibility challenges, restricting market expansion, especially in regions with inadequate healthcare infrastructure and limited insurance coverage.

Market Trends of the Global Diabetic Nephropathy Market

One of the key trends shaping the global diabetic nephropathy market is the rising cost of healthcare, which is driving demand for more cost-effective and efficient treatment solutions. Additionally, the growing emphasis on personalized medicine is revolutionizing disease management by enabling tailored treatment approaches based on individual patient profiles. As the market expands, significant advancements in innovative therapies, including precision medicine, targeted biologics, and novel drug formulations, are expected to emerge. These innovations aim to enhance treatment efficacy, improve patient outcomes, and reduce disease progression. Our analysis reveals that continued investment in research and development will play a crucial role in transforming diabetic nephropathy care, ultimately leading to improved quality of life for affected individuals worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Diabetic Nephropathy Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Diuretics
• Antioxidant Inflammation Modulator
• Angiotensin Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
• Renin Inhibitors
• Calcium Channel Blockers
• Others

Global Diabetic Nephropathy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Type-1 Diabetes
• Type-2 Diabetes

Global Diabetic Nephropathy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parental
• Others

Global Diabetic Nephropathy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Centers
• Others

Global Diabetic Nephropathy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Diabetic Nephropathy Market Size & CAGR (2025-2032)

• North America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations